{"gene":"CBLN2","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":2011,"finding":"CBLN2 (like CBLN1) specifically binds to α and β isoforms of neurexin carrying the splice site 4 insert [NRXs(S4+)] and induces synaptogenesis in cerebellar, hippocampal, and cortical neurons in vitro. CBLN1 and CBLN2 compete with neuroligin 1-mediated synaptogenesis by sharing presynaptic receptor NRXs(S4+). The CBLN2–NRX interaction is insensitive to extracellular Ca2+ concentrations.","method":"In vitro synaptogenesis assay, binding competition assay, Ca2+-sensitivity assay","journal":"The European journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal binding and functional assays, replicated across multiple neuron types in vitro","pmids":["21410790"],"is_preprint":false},{"year":2011,"finding":"CBLN2 binds to the N-terminal domain of GluRδ1 and induces preferentially inhibitory presynaptic differentiation of cultured cortical neurons when added together with GluRδ1-expressing HEK293T cells. The synaptogenic activity of CBLN2 is suppressed by soluble extracellular domain of NRXN1α or NRXN1β(S4), indicating CBLN2 bridges GluRδ1 postsynaptically and NRXNs presynaptically.","method":"Co-culture synaptogenesis assay, direct binding assay (pulldown), HEK293T cell transfection","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal assays (binding + functional synaptogenesis), independently replicated across two papers (PMID 22191730 and 21356198)","pmids":["22191730","21356198"],"is_preprint":false},{"year":2011,"finding":"CBLN1 and CBLN2 show robust binding to NRXN1α and all three β-NRXNs, selective for variants containing splice segment 4 (S4). CBLN2 has lower binding affinity to NRXNs than CBLN1 as measured by surface plasmon resonance. CBLN4 shows much weaker interaction with NRXNs. CBLN2 induces presynaptic differentiation of cortical neurons, with preferentially inhibitory over excitatory presynaptic differentiation compared to neuroligin 1.","method":"Surface plasmon resonance binding assay, in vitro synaptogenesis assay with cultured cortical neurons","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative binding measurements by SPR plus functional synaptogenesis assay, consistent with multiple other papers","pmids":["21356198"],"is_preprint":false},{"year":2007,"finding":"CBLN2 is secreted as an N-linked glycoprotein from mammalian heterologous cells. CBLN2 forms not only homomeric but also heteromeric complexes with other Cbln family members (including CBLN1, CBLN3, CBLN4) in vitro. Heteromer formation can modulate secretion and trafficking of family members.","method":"Transfection of heterologous cells, Western blot, immunoprecipitation, secretion assay","journal":"The European journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — biochemical reconstitution of secretion and complex formation in heterologous cells, multiple family members tested","pmids":["17331201"],"is_preprint":false},{"year":2012,"finding":"CBLN1 and CBLN2 both bind to GluRδ2 and NRXN1-3; ectopic expression of CBLN2 in Purkinje cells of Cbln1-null mice rescues cerebellar synaptic deficits, demonstrating functional redundancy with CBLN1 in the cerebellum mediated through shared receptor binding. However, Cbln2-null mice do not display the striatal synaptic alterations seen in Cbln1-null mice, indicating non-redundant roles in thalamic neurons.","method":"Transgenic rescue (ectopic Cbln2 expression in Purkinje cells of Cbln1-null mice), Cbln2 knockout mouse generation, binding assays, synaptic morphology analysis","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic rescue experiment plus KO mice with defined synaptic phenotype readout, multiple orthogonal approaches","pmids":["22117778"],"is_preprint":false},{"year":2012,"finding":"CBLN4, but not CBLN1 or CBLN2, selectively binds the netrin receptor DCC in a netrin-displaceable fashion. CBLN1 and CBLN2 both bind GluRδ2 and neurexins 1–3, whereas CBLN4 binds weakly or not at all. Heteromeric complexes of CBLN1+CBLN4 have greatly reduced affinity for DCC but increased affinity for neurexins.","method":"Candidate receptor-screening binding assay, netrin displacement assay, co-immunoprecipitation","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor binding assays with multiple controls, single lab study","pmids":["22220752"],"is_preprint":false},{"year":2018,"finding":"GluD1 (δ1 glutamate receptor) requires CBLN2 to assemble and maintain excitatory synapses in the hippocampus. The action of GluD1 is absent in Cbln2 knockout mice. GluD1 actions further require presynaptic neurexin 1β carrying the splice site 4 insert (+S4). Together, CBLN2 forms a tripartite complex linking presynaptic neurexin 1β(+S4) to postsynaptic GluD1 for hippocampal synapse assembly and maintenance.","method":"Cbln2 knockout mice, electrophysiology, synapse density analysis, genetic epistasis with neurexin splice variants","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (KO mice + neurexin splice variant requirement) with electrophysiological and morphological readouts, multiple orthogonal approaches","pmids":["29784783"],"is_preprint":false},{"year":2018,"finding":"Cbln1/2 double-KO (but not single KO) mice exhibit salience-induced seizures, and a selective ~50% decrease in hippocampal excitatory synapse density in the stratum lacunosum moleculare and dentate gyrus of aging (6-month-old) mice, as well as decreased synapse density in striatum and retrosplenial cortex. Cerebellins do not contribute to initial synapse formation but are required for long-term synapse maintenance.","method":"Constitutive single, double, and triple KO mice; synapse density quantification; behavioral testing (seizure assessment, motor behavior)","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple KO combinations with quantitative synapse density and behavioral phenotypes across multiple brain regions and ages","pmids":["29691328"],"is_preprint":false},{"year":2021,"finding":"Constitutive Cbln2 KO mice display robust compulsive behaviors (stereotypic pattern running, marble burying, explosive jumping, excessive nest building) and decreased brain serotonin levels. Conditional deletion of Cbln2 from dorsal raphe neurons or from presynaptic neurons synapsing onto dorsal raphe neurons reproduces compulsive behaviors. Injection of recombinant CBLN2 protein into the dorsal raphe of Cbln2 KO mice largely reverses compulsive behaviors. Serotonin precursor 5-HTP or fluoxetine alleviated compulsive behaviors in Cbln2 KO mice.","method":"Constitutive and conditional KO mice, behavioral assays, HPLC serotonin measurement, recombinant protein injection rescue, pharmacological rescue","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches including conditional KO, rescue with recombinant protein, and pharmacological rescue, all converging on dorsal raphe serotonergic circuit","pmids":["34158618"],"is_preprint":false},{"year":2022,"finding":"At CA1→subiculum synapses, Nrxn1SS4+ and Nrxn3SS4+ act through secreted CBLN2 to activate postsynaptic GluD1: Nrxn1SS4+–CBLN2 signaling enhances NMDA-receptor responses, while Nrxn3SS4+–CBLN2 signaling suppresses AMPA-receptor responses, without affecting synapse formation or number. In the prefrontal cortex, Nrxn1SS4+–CBLN2 signaling selectively controls NMDA-receptors without affecting spine or synapse numbers. Constitutive Cbln2 deletion confirms these functions with no additional developmental synaptogenic role.","method":"Constitutive Cbln2 deletion in mice, electrophysiology (AMPA/NMDA receptor recordings), spine/synapse density quantification in multiple brain regions","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — constitutive KO with circuit-specific electrophysiological dissection across multiple brain regions, multiple receptor subtypes assessed","pmids":["36205393"],"is_preprint":false},{"year":2021,"finding":"Species differences in CBLN2 expression level and laminar distribution in the prefrontal cortex are, at least in part, due to Hominini-specific deletions containing SOX5-binding sites within a retinoic acid-responsive CBLN2 enhancer. In situ genetic humanization of the mouse Cbln2 enhancer drives increased and ectopic laminar Cbln2 expression and promotes prefrontal cortex dendritic spine formation.","method":"Comparative transcriptomics, enhancer analysis, ChIP for SOX5-binding sites, in situ genetic humanization of mouse Cbln2 enhancer, dendritic spine quantification","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — genetic humanization experiment with direct morphological (dendritic spine) phenotype readout, multiple orthogonal methods","pmids":["34599306"],"is_preprint":false},{"year":2024,"finding":"A GRID1 variant in the distal amino-terminal domain at a position predicted to interact with CBLN2/CBLN4 disrupts complex formation between GluD1 and CBLN2, as demonstrated by biochemical assay, potentially perturbing synapse organization.","method":"Site-directed mutagenesis of GluD1 variant, biochemical co-complex assay","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, single biochemical assay demonstrating disrupted GluD1–CBLN2 complex formation by a disease-associated variant","pmids":["37944084"],"is_preprint":false},{"year":2023,"finding":"CBLN2 promotes endothelial-mesenchymal transition (EndMT) in hypoxic pulmonary hypertension by activating the NF-κB/HIF-1α/Twist1 pathway. CBLN2 siRNA, NF-κB inhibitor PDTC, and HIF-1α inhibitor KC7F2 each inhibit hypoxia-induced EndMT in HPAECs.","method":"Hypoxia-induced PH rat model, EndMT cell model, siRNA knockdown, pathway inhibitors, Western blot, immunofluorescence","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal interventions (siRNA + pathway inhibitors) in cell and animal models, single lab","pmids":["37355224"],"is_preprint":false},{"year":2023,"finding":"Retinoic acid (RA) supplementation increases RARα expression and enhances RARα binding to CBLN2 promoters (confirmed by ChIP assay), upregulating CBLN2 expression in the cerebellum of VPA-treated autistic rats and ameliorating motor coordination deficits. This establishes a RARα→CBLN2 transcriptional regulatory axis.","method":"VPA rat autism model, RA supplementation, ChIP assay for RARα at Cbln2 promoter, qPCR, behavioral motor assays","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP assay establishes direct RARα–CBLN2 promoter interaction, functional rescue in animal model, single lab","pmids":["37247722"],"is_preprint":false},{"year":2025,"finding":"SOX11 binds to 12 cis-regulatory elements within the Cbln2 promoter to enhance its transcription following spinal nerve ligation (SNL). CBLN2 expression is persistently upregulated in dorsal root ganglia after SNL. siRNA knockdown of Sox11 or Cbln2 attenuates SNL-induced mechanical allodynia and thermal hyperalgesia. Exogenous CBLN2 activates NF-κB signaling and induces neuronal hyperexcitability; inhibition of NF-κB reduces CBLN2-induced pain hypersensitivity and proinflammatory cytokine production.","method":"ChIP assay (SOX11 at Cbln2 promoter), siRNA knockdown in vivo, intrathecal CBLN2 injection, high-throughput sequencing, NF-κB inhibitor pharmacology, behavioral pain assays","journal":"Neuroscience bulletin","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-validated transcription factor binding + siRNA KD with behavioral readout + exogenous protein with pathway inhibition, single lab","pmids":["41162740"],"is_preprint":false},{"year":2025,"finding":"TET3-mediated demethylation of the Cbln2 promoter drives CBLN2 upregulation in the trigeminal ganglion following partial infraorbital nerve transection (pIONT). Tet3 knockdown alleviates neuropathic pain and downregulates Cbln2. Exogenous CBLN2 potentiates neuronal excitability and activates ERK signaling; inhibition of the MEK/ERK pathway abolishes CBLN2-induced hypersensitivity and suppresses proinflammatory cytokine expression.","method":"Methylation-specific PCR, bisulfite sequencing PCR, siRNA knockdown in vivo, whole-cell patch-clamp, ERK pathway inhibitors, behavioral pain assays","journal":"The journal of headache and pain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (methylation assays + electrophysiology + pharmacology + siRNA), single lab","pmids":["40665237"],"is_preprint":false},{"year":2018,"finding":"CBLN2-derived peptides (3 novel peptides identified by mass spectrometry from dorsal horn spinal cord) induce mechanical hypersensitivity upon intrathecal injection in mice. Two of three CBLN2-derived peptides significantly increased pain responses in the first 6 hours post-injection compared to saline controls.","method":"Mass spectrometry peptide identification from spinal cord, intrathecal injection, von Frey mechanical sensitivity testing","journal":"Neuropeptides","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vivo functional assay with identified CBLN2-derived peptides, single lab, limited mechanistic detail on receptor","pmids":["29705514"],"is_preprint":false},{"year":2024,"finding":"CBLN2 overexpression inhibits STAT3-induced PD-L1 and beta-catenin activation in colorectal cancer cells and inhibits oncogenic properties in vitro and tumor growth in vivo. CBLN2 overexpression improves immune checkpoint blockade efficacy in the MC38 CRC model.","method":"Overexpression in CRC cell lines, in vivo tumor growth assay, Western blot for STAT3/PD-L1/beta-catenin, MC38 syngeneic tumor model with ICB treatment","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo functional assays with pathway mechanistic readout, single lab","pmids":["39577217"],"is_preprint":false},{"year":1994,"finding":"CBLN2 was cloned as a distinct gene from CBLN1; amino acid comparison revealed CBLN2 is 88% identical to the carboxy-terminal region of CBLN1. Southern analysis confirmed they are independent genes. Cbln2 maps to the distal end of mouse chromosome 18.","method":"Molecular cloning, sequence alignment, Southern blot, genetic mapping","journal":"Brain research. Molecular brain research","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct molecular cloning and genomic characterization with Southern confirmation","pmids":["7877445"],"is_preprint":false}],"current_model":"CBLN2 is a secreted glycoprotein that forms homo- and heteromeric (with other CBLN family members) hexameric complexes, binds selectively to presynaptic neurexins carrying splice-site 4 (NRXs[S4+]) and to postsynaptic GluD1 (and GluD2), thereby assembling tripartite trans-synaptic adhesion complexes that are required for long-term synapse maintenance and the circuit-specific regulation of AMPA- and NMDA-receptor responses (rather than initial synaptogenesis); in the dorsal raphe it regulates serotonergic circuits and compulsive behaviors, in the prefrontal cortex its expression is controlled by a Hominini-specific retinoic acid-responsive enhancer (subject to SOX5 regulation) and promotes dendritic spine formation, in pain pathways CBLN2 is upregulated via SOX11-driven transcription and TET3-mediated promoter demethylation and activates NF-κB/ERK signaling to drive neuroinflammation and hyperexcitability, and in pulmonary endothelial cells it promotes endothelial–mesenchymal transition via NF-κB/HIF-1α/Twist1."},"narrative":{"mechanistic_narrative":"CBLN2 is a secreted N-linked glycoprotein of the cerebellin family that functions as a trans-synaptic organizer, bridging presynaptic neurexins to postsynaptic delta-type glutamate receptors to maintain synapses and tune receptor signaling [PMID:17331201, PMID:29784783]. It forms homomeric and heteromeric complexes with other cerebellins (CBLN1, CBLN3, CBLN4), and heteromer formation modulates secretion and receptor affinity [PMID:17331201, PMID:22220752]. CBLN2 binds selectively to α- and β-neurexins carrying the splice site 4 insert [NRXs(S4+)] in a Ca2+-independent manner and simultaneously to postsynaptic GluD1/GluD2 (GluRδ1/δ2), assembling a tripartite neurexin–CBLN2–GluD complex; through this complex it induces presynaptic differentiation in cultured cerebellar, hippocampal, and cortical neurons, with a preference for inhibitory differentiation relative to neuroligin 1 [PMID:21410790, PMID:22191730, PMID:21356198, PMID:29784783]. In vivo, CBLN2 is required not for initial synaptogenesis but for long-term synapse maintenance and circuit-specific control of glutamate receptor responses: at CA1→subiculum and prefrontal synapses, Nrxn1SS4+–CBLN2 signaling enhances NMDA-receptor responses while Nrxn3SS4+–CBLN2 signaling suppresses AMPA-receptor responses, and Cbln1/2 loss reduces hippocampal excitatory synapse density in aging mice and produces salience-induced seizures [PMID:29691328, PMID:36205393]. It shows partial functional redundancy with CBLN1 in cerebellum yet non-redundant roles in other circuits [PMID:22117778]. In the dorsal raphe, CBLN2 regulates serotonergic circuits, and its loss produces compulsive behaviors reversible by recombinant CBLN2 or serotonergic drugs [PMID:34158618]. CBLN2 transcription is controlled by retinoic-acid signaling through a RARα-bound promoter and a Hominini-specific enhancer subject to SOX5 regulation that drives prefrontal dendritic spine formation [PMID:34599306, PMID:37247722]. Beyond the nervous system, CBLN2 acts in disease contexts: it is induced in sensory ganglia via SOX11-driven transcription and TET3-mediated promoter demethylation to drive neuropathic pain through NF-κB and ERK signaling [PMID:41162740, PMID:40665237], promotes pulmonary endothelial–mesenchymal transition via NF-κB/HIF-1α/Twist1 [PMID:37355224], and suppresses oncogenic STAT3/PD-L1/β-catenin signaling in colorectal cancer [PMID:39577217].","teleology":[{"year":1994,"claim":"Established CBLN2 as a gene distinct from CBLN1, defining the molecular identity that all subsequent functional work would build upon.","evidence":"Molecular cloning, sequence alignment, Southern blot, and genetic mapping in mouse","pmids":["7877445"],"confidence":"High","gaps":["No functional role assigned at cloning","Protein product and secretion not characterized"]},{"year":2007,"claim":"Showed CBLN2 is a secreted glycoprotein capable of homo- and heteromeric assembly with other cerebellins, defining it as a secreted oligomeric signaling molecule rather than a cell-intrinsic factor.","evidence":"Heterologous cell transfection, Western blot, immunoprecipitation, and secretion assay","pmids":["17331201"],"confidence":"High","gaps":["Receptors and synaptic targets not yet identified","Stoichiometry of native complexes not resolved"]},{"year":2011,"claim":"Identified the dual receptor system — presynaptic NRXs(S4+) and postsynaptic GluRδ1/δ2 — establishing CBLN2 as a bidirectional synaptic bridge that competes with neuroligin-mediated synaptogenesis.","evidence":"In vitro and co-culture synaptogenesis assays, pulldown binding, surface plasmon resonance, and Ca2+-sensitivity testing in cultured neurons","pmids":["21410790","22191730","21356198"],"confidence":"High","gaps":["In vivo relevance of in vitro synaptogenesis unestablished","Preference for inhibitory vs excitatory differentiation mechanism unclear"]},{"year":2012,"claim":"Defined CBLN2's place within the cerebellin family by demonstrating shared GluRδ2/neurexin binding and functional redundancy with CBLN1 in cerebellum but non-redundant roles elsewhere, and distinguished it from the DCC-binding CBLN4.","evidence":"Transgenic rescue of Cbln1-null Purkinje cells, Cbln2 knockout mice, receptor binding and displacement assays","pmids":["22117778","22220752"],"confidence":"High","gaps":["Circuit basis of non-redundant thalamic role not defined","CBLN4-receptor finding is Medium-confidence single-lab"]},{"year":2018,"claim":"Reframed CBLN2 from a synaptogenic factor to a maintenance factor by showing it assembles a tripartite NRX1β(S4+)–CBLN2–GluD1 complex required for long-term hippocampal synapse maintenance, not initial formation.","evidence":"Cbln2 single, double, and triple KO mice, electrophysiology, synapse density quantification, and seizure/behavioral phenotyping","pmids":["29784783","29691328"],"confidence":"High","gaps":["Molecular mechanism distinguishing maintenance from formation unresolved","Why deficits manifest in aging not explained"]},{"year":2021,"claim":"Linked CBLN2 to a behavioral circuit by showing it regulates dorsal raphe serotonergic function, with loss causing compulsive behavior reversible by recombinant protein and serotonergic drugs.","evidence":"Constitutive and conditional KO mice, behavioral assays, HPLC serotonin measurement, recombinant protein and pharmacological rescue","pmids":["34158618"],"confidence":"High","gaps":["Synaptic substrate within raphe circuits not identified","Connection between serotonin loss and synaptic role unclear"]},{"year":2021,"claim":"Established RARα/retinoic-acid and a Hominini-specific SOX5-regulated enhancer as transcriptional drivers of CBLN2 controlling prefrontal expression and dendritic spine formation, providing an evolutionary and regulatory dimension.","evidence":"Comparative transcriptomics, enhancer/ChIP analysis, in situ genetic humanization of the mouse enhancer, dendritic spine quantification, and RA supplementation with RARα ChIP in a VPA autism model","pmids":["34599306","37247722"],"confidence":"High","gaps":["Direct link from enhancer-driven expression to specific synaptic outputs incomplete","VPA-model RARα axis is Medium-confidence single lab"]},{"year":2022,"claim":"Dissected circuit-specific receptor signaling, showing distinct neurexin splice isoforms route through CBLN2–GluD1 to oppositely modulate NMDA vs AMPA receptor responses without changing synapse number.","evidence":"Constitutive Cbln2 deletion, circuit-specific electrophysiology of AMPA/NMDA responses, spine/synapse density quantification across brain regions","pmids":["36205393"],"confidence":"High","gaps":["Downstream signaling from GluD1 to receptor modulation not defined","How a single ligand produces opposite outputs is unresolved"]},{"year":2024,"claim":"Provided a disease-relevant structural anchor by showing a GRID1/GluD1 amino-terminal variant disrupts GluD1–CBLN2 complex formation, implicating the interaction in synaptopathology.","evidence":"Site-directed mutagenesis and biochemical co-complex assay","pmids":["37944084"],"confidence":"Medium","gaps":["Single biochemical assay without in vivo synaptic readout","Disease causality not established"]},{"year":2025,"claim":"Extended CBLN2 beyond synaptic maintenance into pathological signaling by showing transcriptional/epigenetic induction (SOX11, TET3 demethylation) drives neuropathic pain through NF-κB and ERK, and that CBLN2 acts in non-neural disease via NF-κB/HIF-1α/Twist1 in pulmonary endothelium and STAT3/PD-L1/β-catenin in colorectal cancer.","evidence":"ChIP, methylation assays, in vivo siRNA knockdown, exogenous protein and pathway inhibitors with behavioral, electrophysiological, and tumor readouts; plus overexpression/EndMT cell and animal models","pmids":["41162740","40665237","37355224","39577217","29705514"],"confidence":"Medium","gaps":["Receptor mediating pro-inflammatory/EndMT signaling not identified","Relationship between synaptic NRX/GluD function and non-neural signaling unknown","All single-lab findings"]},{"year":null,"claim":"How CBLN2–GluD1 engagement transduces opposite, circuit-specific modulation of AMPA versus NMDA receptors and what receptor mediates its non-synaptic NF-κB/ERK/HIF-1α actions remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No downstream signaling mechanism from GluD1 defined","No receptor identified for peripheral/disease signaling","No structural model of the native tripartite complex"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,1,6]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[6,9]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[1,6]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3,8]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[6,9]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[10]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,6]}],"complexes":["neurexin(S4+)–CBLN2–GluD1 tripartite trans-synaptic complex"],"partners":["NRXN1","NRXN3","GRID1","GRID2","CBLN1","CBLN4","RARA","SOX5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8IUK8","full_name":"Cerebellin-2","aliases":[],"length_aa":224,"mass_kda":24.1,"function":"Acts as a synaptic organizer in specific subsets of neurons in the brain. Essential for long-term maintenance but not establishment of excitatory synapses. Functions as part of a trans-synaptic complex by binding to postsynaptic GRID1 and presynaptic neurexins. This interaction helps regulate the activity of NMDA and AMPA receptors at hippocampal synapses without affecting synapse formation. NRXN1B-CBLN2-GRID1 complex transduce presynaptic signals into postsynaptic NMDAR response. NRXN3B-CBLN2-GRID1 complex transduce presynaptic signals into postsynaptic AMPAR response","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q8IUK8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CBLN2","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CBLN2","total_profiled":1310},"omim":[{"mim_id":"615029","title":"PRECEREBELLIN 4; CBLN4","url":"https://www.omim.org/entry/615029"},{"mim_id":"612978","title":"PRECEREBELLIN 3; CBLN3","url":"https://www.omim.org/entry/612978"},{"mim_id":"600433","title":"PRECEREBELLIN 2; CBLN2","url":"https://www.omim.org/entry/600433"},{"mim_id":"600432","title":"PRECEREBELLIN 1; CBLN1","url":"https://www.omim.org/entry/600432"},{"mim_id":"178600","title":"PULMONARY HYPERTENSION, PRIMARY, 1; PPH1","url":"https://www.omim.org/entry/178600"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Flagellar centriole","reliability":"Approved"},{"location":"Mid piece","reliability":"Approved"},{"location":"Principal piece","reliability":"Approved"},{"location":"Perinuclear theca","reliability":"Additional"},{"location":"Calyx","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":38.4}],"url":"https://www.proteinatlas.org/search/CBLN2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q8IUK8","domains":[{"cath_id":"2.60.120.40","chopping":"90-222","consensus_level":"high","plddt":93.6551,"start":90,"end":222}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IUK8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IUK8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IUK8-F1-predicted_aligned_error_v6.png","plddt_mean":75.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CBLN2","jax_strain_url":"https://www.jax.org/strain/search?query=CBLN2"},"sequence":{"accession":"Q8IUK8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8IUK8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8IUK8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IUK8"}},"corpus_meta":[{"pmid":"21410790","id":"PMC_21410790","title":"Cbln family proteins promote synapse formation by regulating distinct neurexin signaling pathways in various brain regions.","date":"2011","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21410790","citation_count":134,"is_preprint":false},{"pmid":"16930405","id":"PMC_16930405","title":"Distinct expression of Cbln family mRNAs in developing and adult mouse brains.","date":"2006","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16930405","citation_count":92,"is_preprint":false},{"pmid":"22948383","id":"PMC_22948383","title":"Pathogenetic model for Tourette syndrome delineates overlap with related neurodevelopmental disorders including Autism.","date":"2012","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22948383","citation_count":89,"is_preprint":false},{"pmid":"23502781","id":"PMC_23502781","title":"Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23502781","citation_count":89,"is_preprint":false},{"pmid":"34599306","id":"PMC_34599306","title":"Hominini-specific regulation of CBLN2 increases prefrontal spinogenesis.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34599306","citation_count":64,"is_preprint":false},{"pmid":"18278437","id":"PMC_18278437","title":"Cbln and C1q family proteins: new transneuronal cytokines.","date":"2008","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/18278437","citation_count":64,"is_preprint":false},{"pmid":"24442418","id":"PMC_24442418","title":"The genetic basis of pulmonary arterial hypertension.","date":"2014","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24442418","citation_count":60,"is_preprint":false},{"pmid":"29691328","id":"PMC_29691328","title":"Genetic Ablation of All Cerebellins Reveals Synapse Organizer Functions in Multiple Regions Throughout the Brain.","date":"2018","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29691328","citation_count":59,"is_preprint":false},{"pmid":"23651021","id":"PMC_23651021","title":"GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis.","date":"2013","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/23651021","citation_count":59,"is_preprint":false},{"pmid":"22191730","id":"PMC_22191730","title":"Glutamate receptor δ1 induces preferentially inhibitory presynaptic differentiation of cortical neurons by interacting with neurexins through cerebellin precursor protein subtypes.","date":"2012","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22191730","citation_count":58,"is_preprint":false},{"pmid":"28714144","id":"PMC_28714144","title":"Cerebellins are differentially expressed in selective subsets of neurons throughout the brain.","date":"2017","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28714144","citation_count":56,"is_preprint":false},{"pmid":"22220752","id":"PMC_22220752","title":"The Cbln family of proteins interact with multiple signaling pathways.","date":"2012","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22220752","citation_count":52,"is_preprint":false},{"pmid":"29784783","id":"PMC_29784783","title":"Postsynaptic δ1 glutamate receptor assembles and maintains hippocampal synapses via Cbln2 and neurexin.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29784783","citation_count":49,"is_preprint":false},{"pmid":"17331201","id":"PMC_17331201","title":"Characterization of a transneuronal cytokine family Cbln--regulation of secretion by heteromeric assembly.","date":"2007","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17331201","citation_count":47,"is_preprint":false},{"pmid":"21356198","id":"PMC_21356198","title":"Differential interactions of cerebellin precursor protein (Cbln) subtypes and neurexin variants for synapse formation of cortical neurons.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21356198","citation_count":46,"is_preprint":false},{"pmid":"34318750","id":"PMC_34318750","title":"Transcriptomic encoding of sensorimotor transformation in the midbrain.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34318750","citation_count":45,"is_preprint":false},{"pmid":"34932943","id":"PMC_34932943","title":"A brain-to-spinal sensorimotor loop for repetitive self-grooming.","date":"2021","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/34932943","citation_count":33,"is_preprint":false},{"pmid":"18001291","id":"PMC_18001291","title":"Mapping of Cbln1-like immunoreactivity in adult and developing mouse brain and its localization to the endolysosomal compartment of neurons.","date":"2007","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18001291","citation_count":31,"is_preprint":false},{"pmid":"22117778","id":"PMC_22117778","title":"Comparison of Cbln1 and Cbln2 functions using transgenic and knockout mice.","date":"2012","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22117778","citation_count":30,"is_preprint":false},{"pmid":"24078385","id":"PMC_24078385","title":"Genetics and the molecular pathogenesis of pulmonary arterial hypertension.","date":"2013","source":"Current hypertension reports","url":"https://pubmed.ncbi.nlm.nih.gov/24078385","citation_count":29,"is_preprint":false},{"pmid":"36205393","id":"PMC_36205393","title":"Distinct neurexin-cerebellin complexes control AMPA- and NMDA-receptor responses in a circuit-dependent manner.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/36205393","citation_count":27,"is_preprint":false},{"pmid":"34158618","id":"PMC_34158618","title":"Cerebellin-2 regulates a serotonergic dorsal raphe circuit that controls compulsive behaviors.","date":"2021","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/34158618","citation_count":24,"is_preprint":false},{"pmid":"34685624","id":"PMC_34685624","title":"Dysfunction of Glutamate Delta-1 Receptor-Cerebellin 1 Trans-Synaptic Signaling in the Central Amygdala in Chronic Pain.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34685624","citation_count":24,"is_preprint":false},{"pmid":"37984853","id":"PMC_37984853","title":"Sex-specific genetic architecture of late-life memory performance.","date":"2023","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/37984853","citation_count":23,"is_preprint":false},{"pmid":"7877445","id":"PMC_7877445","title":"Genomic structure and mapping of precerebellin and a precerebellin-related gene.","date":"1994","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/7877445","citation_count":22,"is_preprint":false},{"pmid":"26820968","id":"PMC_26820968","title":"High Frequency of Pulmonary Hypertension-Causing Gene Mutation in Chinese Patients with Chronic Thromboembolic Pulmonary Hypertension.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26820968","citation_count":21,"is_preprint":false},{"pmid":"37355224","id":"PMC_37355224","title":"Cerebellin-2 promotes endothelial-mesenchymal transition in hypoxic pulmonary hypertension rats by activating NF-κB/HIF-1α/Twist1 pathway.","date":"2023","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37355224","citation_count":19,"is_preprint":false},{"pmid":"26173551","id":"PMC_26173551","title":"A New Genomewide Association Meta-Analysis of Alcohol Dependence.","date":"2015","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/26173551","citation_count":19,"is_preprint":false},{"pmid":"21456003","id":"PMC_21456003","title":"Localization of cerebellin-2 in late embryonic chicken brain: implications for a role in synapse formation and for brain evolution.","date":"2011","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21456003","citation_count":19,"is_preprint":false},{"pmid":"18813864","id":"PMC_18813864","title":"Expression of precerebellins in cultured rat calvaria osteoblast-like cells.","date":"2008","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18813864","citation_count":16,"is_preprint":false},{"pmid":"19082514","id":"PMC_19082514","title":"Precerebellin-related genes and precerebellin 1 peptide in endocrine glands of the rat - pattern of their expression.","date":"2009","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19082514","citation_count":14,"is_preprint":false},{"pmid":"37944084","id":"PMC_37944084","title":"Clinical features, functional consequences, and rescue pharmacology of missense GRID1 and GRID2 human variants.","date":"2024","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37944084","citation_count":13,"is_preprint":false},{"pmid":"34182539","id":"PMC_34182539","title":"Development and validation of a risk prediction model and nomogram for colon adenocarcinoma based on methylation-driven genes.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34182539","citation_count":12,"is_preprint":false},{"pmid":"34234169","id":"PMC_34234169","title":"A high plane of nutrition during early life alters the hypothalamic transcriptome of heifer calves.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34234169","citation_count":11,"is_preprint":false},{"pmid":"29705514","id":"PMC_29705514","title":"Spinal injection of newly identified cerebellin-1 and cerebellin-2 peptides induce mechanical hypersensitivity in mice.","date":"2018","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/29705514","citation_count":11,"is_preprint":false},{"pmid":"37247722","id":"PMC_37247722","title":"Retinoic acid supplementation ameliorates motor incoordination via RARα-CBLN2 in the cerebellum of a prenatal valproic acid-exposed rat autism model.","date":"2023","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/37247722","citation_count":9,"is_preprint":false},{"pmid":"20506477","id":"PMC_20506477","title":"Identification of cerebellin2 in chick and its preferential expression by subsets of developing sensory neurons and their targets in the dorsal horn.","date":"2010","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20506477","citation_count":9,"is_preprint":false},{"pmid":"23853053","id":"PMC_23853053","title":"Parcellation of cerebellins 1, 2, and 4 among different subpopulations of dorsal horn neurons in mouse spinal cord.","date":"2014","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23853053","citation_count":9,"is_preprint":false},{"pmid":"19212655","id":"PMC_19212655","title":"Precerebellin-related genes and precerebellin 1 peptide in the adrenal gland of the rat: expression pattern, localization, developmental regulation and effects on corticosteroidogenesis.","date":"2009","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19212655","citation_count":7,"is_preprint":false},{"pmid":"37895006","id":"PMC_37895006","title":"Effects of Mitochondrial Transplantation on Transcriptomics in a Polymicrobial Sepsis Model.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37895006","citation_count":5,"is_preprint":false},{"pmid":"41162740","id":"PMC_41162740","title":"SOX11-mediated CBLN2 Upregulation Contributes to Neuropathic Pain through NF-κB-Driven Neuroinflammation in Dorsal Root Ganglia of Mice.","date":"2025","source":"Neuroscience bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/41162740","citation_count":3,"is_preprint":false},{"pmid":"40448997","id":"PMC_40448997","title":"Cell-death pathways and tau-associated neuronal vulnerability in Alzheimer's disease.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/40448997","citation_count":3,"is_preprint":false},{"pmid":"38906038","id":"PMC_38906038","title":"A systematic approach introduced some immune system targets in rectal cancer by considering cell-free DNA methylation in response to radiochemotherapy.","date":"2024","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/38906038","citation_count":2,"is_preprint":false},{"pmid":"39577217","id":"PMC_39577217","title":"CBLN2 overexpression inhibits colorectal cancer progression and improves immunotherapy responses.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39577217","citation_count":1,"is_preprint":false},{"pmid":"40665237","id":"PMC_40665237","title":"Promoter demethylation of cerebellin 2 by ten-eleven translocation 3 contributes to peripheral sensitization in trigeminal neuropathic pain of mice.","date":"2025","source":"The journal of headache and pain","url":"https://pubmed.ncbi.nlm.nih.gov/40665237","citation_count":1,"is_preprint":false},{"pmid":"40033254","id":"PMC_40033254","title":"Histone H3 lysine 9 tri-methylation is associated with pterygium.","date":"2025","source":"BMC ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/40033254","citation_count":1,"is_preprint":false},{"pmid":"41794023","id":"PMC_41794023","title":"CBLN2 promoter enables genetic access to wide-field neurons of the tree shrew superior colliculus.","date":"2026","source":"Cell reports methods","url":"https://pubmed.ncbi.nlm.nih.gov/41794023","citation_count":0,"is_preprint":false},{"pmid":"42101182","id":"PMC_42101182","title":"Expression of sulfate pathway genes in human neurodevelopment.","date":"2026","source":"Journal of neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/42101182","citation_count":0,"is_preprint":false},{"pmid":"40736440","id":"PMC_40736440","title":"Granulosa-cumulus cells global transcriptome sequencing as a predictor of embryo development: a preliminary study.","date":"2025","source":"Minerva obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/40736440","citation_count":0,"is_preprint":false},{"pmid":"40909808","id":"PMC_40909808","title":"Mouse Gnal transcripts and transcriptomics in isolated dystonia.","date":"2025","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/40909808","citation_count":0,"is_preprint":false},{"pmid":"41995212","id":"PMC_41995212","title":"Structural Architecture and Evolutionary Conservation of Cerebellin-Mediated Trans-Synaptic Signaling.","date":"2026","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/41995212","citation_count":0,"is_preprint":false},{"pmid":"42068085","id":"PMC_42068085","title":"Excitatory neurons and astrocytes-specific dysregulation and aberrant interactions are vulnerable to FCDI as suggested by single-cell spatial transcriptomics.","date":"2026","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/42068085","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.22.644777","title":"<i>Cerebellin-2</i>  neurons in the parafascicular thalamic nucleus regulate self-grooming behavior","date":"2025-03-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.22.644777","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.20.629854","title":"A molecularly defined brain circuit module for regulating the panic-like defensive state","date":"2024-12-21","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.20.629854","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":29701,"output_tokens":5255,"usd":0.083964,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13691,"output_tokens":4087,"usd":0.085315,"stage2_stop_reason":"end_turn"},"total_usd":0.169279,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"CBLN2 (like CBLN1) specifically binds to α and β isoforms of neurexin carrying the splice site 4 insert [NRXs(S4+)] and induces synaptogenesis in cerebellar, hippocampal, and cortical neurons in vitro. CBLN1 and CBLN2 compete with neuroligin 1-mediated synaptogenesis by sharing presynaptic receptor NRXs(S4+). The CBLN2–NRX interaction is insensitive to extracellular Ca2+ concentrations.\",\n      \"method\": \"In vitro synaptogenesis assay, binding competition assay, Ca2+-sensitivity assay\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal binding and functional assays, replicated across multiple neuron types in vitro\",\n      \"pmids\": [\"21410790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CBLN2 binds to the N-terminal domain of GluRδ1 and induces preferentially inhibitory presynaptic differentiation of cultured cortical neurons when added together with GluRδ1-expressing HEK293T cells. The synaptogenic activity of CBLN2 is suppressed by soluble extracellular domain of NRXN1α or NRXN1β(S4), indicating CBLN2 bridges GluRδ1 postsynaptically and NRXNs presynaptically.\",\n      \"method\": \"Co-culture synaptogenesis assay, direct binding assay (pulldown), HEK293T cell transfection\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal assays (binding + functional synaptogenesis), independently replicated across two papers (PMID 22191730 and 21356198)\",\n      \"pmids\": [\"22191730\", \"21356198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CBLN1 and CBLN2 show robust binding to NRXN1α and all three β-NRXNs, selective for variants containing splice segment 4 (S4). CBLN2 has lower binding affinity to NRXNs than CBLN1 as measured by surface plasmon resonance. CBLN4 shows much weaker interaction with NRXNs. CBLN2 induces presynaptic differentiation of cortical neurons, with preferentially inhibitory over excitatory presynaptic differentiation compared to neuroligin 1.\",\n      \"method\": \"Surface plasmon resonance binding assay, in vitro synaptogenesis assay with cultured cortical neurons\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative binding measurements by SPR plus functional synaptogenesis assay, consistent with multiple other papers\",\n      \"pmids\": [\"21356198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CBLN2 is secreted as an N-linked glycoprotein from mammalian heterologous cells. CBLN2 forms not only homomeric but also heteromeric complexes with other Cbln family members (including CBLN1, CBLN3, CBLN4) in vitro. Heteromer formation can modulate secretion and trafficking of family members.\",\n      \"method\": \"Transfection of heterologous cells, Western blot, immunoprecipitation, secretion assay\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — biochemical reconstitution of secretion and complex formation in heterologous cells, multiple family members tested\",\n      \"pmids\": [\"17331201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CBLN1 and CBLN2 both bind to GluRδ2 and NRXN1-3; ectopic expression of CBLN2 in Purkinje cells of Cbln1-null mice rescues cerebellar synaptic deficits, demonstrating functional redundancy with CBLN1 in the cerebellum mediated through shared receptor binding. However, Cbln2-null mice do not display the striatal synaptic alterations seen in Cbln1-null mice, indicating non-redundant roles in thalamic neurons.\",\n      \"method\": \"Transgenic rescue (ectopic Cbln2 expression in Purkinje cells of Cbln1-null mice), Cbln2 knockout mouse generation, binding assays, synaptic morphology analysis\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic rescue experiment plus KO mice with defined synaptic phenotype readout, multiple orthogonal approaches\",\n      \"pmids\": [\"22117778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CBLN4, but not CBLN1 or CBLN2, selectively binds the netrin receptor DCC in a netrin-displaceable fashion. CBLN1 and CBLN2 both bind GluRδ2 and neurexins 1–3, whereas CBLN4 binds weakly or not at all. Heteromeric complexes of CBLN1+CBLN4 have greatly reduced affinity for DCC but increased affinity for neurexins.\",\n      \"method\": \"Candidate receptor-screening binding assay, netrin displacement assay, co-immunoprecipitation\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor binding assays with multiple controls, single lab study\",\n      \"pmids\": [\"22220752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GluD1 (δ1 glutamate receptor) requires CBLN2 to assemble and maintain excitatory synapses in the hippocampus. The action of GluD1 is absent in Cbln2 knockout mice. GluD1 actions further require presynaptic neurexin 1β carrying the splice site 4 insert (+S4). Together, CBLN2 forms a tripartite complex linking presynaptic neurexin 1β(+S4) to postsynaptic GluD1 for hippocampal synapse assembly and maintenance.\",\n      \"method\": \"Cbln2 knockout mice, electrophysiology, synapse density analysis, genetic epistasis with neurexin splice variants\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (KO mice + neurexin splice variant requirement) with electrophysiological and morphological readouts, multiple orthogonal approaches\",\n      \"pmids\": [\"29784783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cbln1/2 double-KO (but not single KO) mice exhibit salience-induced seizures, and a selective ~50% decrease in hippocampal excitatory synapse density in the stratum lacunosum moleculare and dentate gyrus of aging (6-month-old) mice, as well as decreased synapse density in striatum and retrosplenial cortex. Cerebellins do not contribute to initial synapse formation but are required for long-term synapse maintenance.\",\n      \"method\": \"Constitutive single, double, and triple KO mice; synapse density quantification; behavioral testing (seizure assessment, motor behavior)\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple KO combinations with quantitative synapse density and behavioral phenotypes across multiple brain regions and ages\",\n      \"pmids\": [\"29691328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Constitutive Cbln2 KO mice display robust compulsive behaviors (stereotypic pattern running, marble burying, explosive jumping, excessive nest building) and decreased brain serotonin levels. Conditional deletion of Cbln2 from dorsal raphe neurons or from presynaptic neurons synapsing onto dorsal raphe neurons reproduces compulsive behaviors. Injection of recombinant CBLN2 protein into the dorsal raphe of Cbln2 KO mice largely reverses compulsive behaviors. Serotonin precursor 5-HTP or fluoxetine alleviated compulsive behaviors in Cbln2 KO mice.\",\n      \"method\": \"Constitutive and conditional KO mice, behavioral assays, HPLC serotonin measurement, recombinant protein injection rescue, pharmacological rescue\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches including conditional KO, rescue with recombinant protein, and pharmacological rescue, all converging on dorsal raphe serotonergic circuit\",\n      \"pmids\": [\"34158618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"At CA1→subiculum synapses, Nrxn1SS4+ and Nrxn3SS4+ act through secreted CBLN2 to activate postsynaptic GluD1: Nrxn1SS4+–CBLN2 signaling enhances NMDA-receptor responses, while Nrxn3SS4+–CBLN2 signaling suppresses AMPA-receptor responses, without affecting synapse formation or number. In the prefrontal cortex, Nrxn1SS4+–CBLN2 signaling selectively controls NMDA-receptors without affecting spine or synapse numbers. Constitutive Cbln2 deletion confirms these functions with no additional developmental synaptogenic role.\",\n      \"method\": \"Constitutive Cbln2 deletion in mice, electrophysiology (AMPA/NMDA receptor recordings), spine/synapse density quantification in multiple brain regions\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — constitutive KO with circuit-specific electrophysiological dissection across multiple brain regions, multiple receptor subtypes assessed\",\n      \"pmids\": [\"36205393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Species differences in CBLN2 expression level and laminar distribution in the prefrontal cortex are, at least in part, due to Hominini-specific deletions containing SOX5-binding sites within a retinoic acid-responsive CBLN2 enhancer. In situ genetic humanization of the mouse Cbln2 enhancer drives increased and ectopic laminar Cbln2 expression and promotes prefrontal cortex dendritic spine formation.\",\n      \"method\": \"Comparative transcriptomics, enhancer analysis, ChIP for SOX5-binding sites, in situ genetic humanization of mouse Cbln2 enhancer, dendritic spine quantification\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genetic humanization experiment with direct morphological (dendritic spine) phenotype readout, multiple orthogonal methods\",\n      \"pmids\": [\"34599306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A GRID1 variant in the distal amino-terminal domain at a position predicted to interact with CBLN2/CBLN4 disrupts complex formation between GluD1 and CBLN2, as demonstrated by biochemical assay, potentially perturbing synapse organization.\",\n      \"method\": \"Site-directed mutagenesis of GluD1 variant, biochemical co-complex assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, single biochemical assay demonstrating disrupted GluD1–CBLN2 complex formation by a disease-associated variant\",\n      \"pmids\": [\"37944084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CBLN2 promotes endothelial-mesenchymal transition (EndMT) in hypoxic pulmonary hypertension by activating the NF-κB/HIF-1α/Twist1 pathway. CBLN2 siRNA, NF-κB inhibitor PDTC, and HIF-1α inhibitor KC7F2 each inhibit hypoxia-induced EndMT in HPAECs.\",\n      \"method\": \"Hypoxia-induced PH rat model, EndMT cell model, siRNA knockdown, pathway inhibitors, Western blot, immunofluorescence\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal interventions (siRNA + pathway inhibitors) in cell and animal models, single lab\",\n      \"pmids\": [\"37355224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Retinoic acid (RA) supplementation increases RARα expression and enhances RARα binding to CBLN2 promoters (confirmed by ChIP assay), upregulating CBLN2 expression in the cerebellum of VPA-treated autistic rats and ameliorating motor coordination deficits. This establishes a RARα→CBLN2 transcriptional regulatory axis.\",\n      \"method\": \"VPA rat autism model, RA supplementation, ChIP assay for RARα at Cbln2 promoter, qPCR, behavioral motor assays\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP assay establishes direct RARα–CBLN2 promoter interaction, functional rescue in animal model, single lab\",\n      \"pmids\": [\"37247722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SOX11 binds to 12 cis-regulatory elements within the Cbln2 promoter to enhance its transcription following spinal nerve ligation (SNL). CBLN2 expression is persistently upregulated in dorsal root ganglia after SNL. siRNA knockdown of Sox11 or Cbln2 attenuates SNL-induced mechanical allodynia and thermal hyperalgesia. Exogenous CBLN2 activates NF-κB signaling and induces neuronal hyperexcitability; inhibition of NF-κB reduces CBLN2-induced pain hypersensitivity and proinflammatory cytokine production.\",\n      \"method\": \"ChIP assay (SOX11 at Cbln2 promoter), siRNA knockdown in vivo, intrathecal CBLN2 injection, high-throughput sequencing, NF-κB inhibitor pharmacology, behavioral pain assays\",\n      \"journal\": \"Neuroscience bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-validated transcription factor binding + siRNA KD with behavioral readout + exogenous protein with pathway inhibition, single lab\",\n      \"pmids\": [\"41162740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TET3-mediated demethylation of the Cbln2 promoter drives CBLN2 upregulation in the trigeminal ganglion following partial infraorbital nerve transection (pIONT). Tet3 knockdown alleviates neuropathic pain and downregulates Cbln2. Exogenous CBLN2 potentiates neuronal excitability and activates ERK signaling; inhibition of the MEK/ERK pathway abolishes CBLN2-induced hypersensitivity and suppresses proinflammatory cytokine expression.\",\n      \"method\": \"Methylation-specific PCR, bisulfite sequencing PCR, siRNA knockdown in vivo, whole-cell patch-clamp, ERK pathway inhibitors, behavioral pain assays\",\n      \"journal\": \"The journal of headache and pain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (methylation assays + electrophysiology + pharmacology + siRNA), single lab\",\n      \"pmids\": [\"40665237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CBLN2-derived peptides (3 novel peptides identified by mass spectrometry from dorsal horn spinal cord) induce mechanical hypersensitivity upon intrathecal injection in mice. Two of three CBLN2-derived peptides significantly increased pain responses in the first 6 hours post-injection compared to saline controls.\",\n      \"method\": \"Mass spectrometry peptide identification from spinal cord, intrathecal injection, von Frey mechanical sensitivity testing\",\n      \"journal\": \"Neuropeptides\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vivo functional assay with identified CBLN2-derived peptides, single lab, limited mechanistic detail on receptor\",\n      \"pmids\": [\"29705514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CBLN2 overexpression inhibits STAT3-induced PD-L1 and beta-catenin activation in colorectal cancer cells and inhibits oncogenic properties in vitro and tumor growth in vivo. CBLN2 overexpression improves immune checkpoint blockade efficacy in the MC38 CRC model.\",\n      \"method\": \"Overexpression in CRC cell lines, in vivo tumor growth assay, Western blot for STAT3/PD-L1/beta-catenin, MC38 syngeneic tumor model with ICB treatment\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo functional assays with pathway mechanistic readout, single lab\",\n      \"pmids\": [\"39577217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CBLN2 was cloned as a distinct gene from CBLN1; amino acid comparison revealed CBLN2 is 88% identical to the carboxy-terminal region of CBLN1. Southern analysis confirmed they are independent genes. Cbln2 maps to the distal end of mouse chromosome 18.\",\n      \"method\": \"Molecular cloning, sequence alignment, Southern blot, genetic mapping\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct molecular cloning and genomic characterization with Southern confirmation\",\n      \"pmids\": [\"7877445\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CBLN2 is a secreted glycoprotein that forms homo- and heteromeric (with other CBLN family members) hexameric complexes, binds selectively to presynaptic neurexins carrying splice-site 4 (NRXs[S4+]) and to postsynaptic GluD1 (and GluD2), thereby assembling tripartite trans-synaptic adhesion complexes that are required for long-term synapse maintenance and the circuit-specific regulation of AMPA- and NMDA-receptor responses (rather than initial synaptogenesis); in the dorsal raphe it regulates serotonergic circuits and compulsive behaviors, in the prefrontal cortex its expression is controlled by a Hominini-specific retinoic acid-responsive enhancer (subject to SOX5 regulation) and promotes dendritic spine formation, in pain pathways CBLN2 is upregulated via SOX11-driven transcription and TET3-mediated promoter demethylation and activates NF-κB/ERK signaling to drive neuroinflammation and hyperexcitability, and in pulmonary endothelial cells it promotes endothelial–mesenchymal transition via NF-κB/HIF-1α/Twist1.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CBLN2 is a secreted N-linked glycoprotein of the cerebellin family that functions as a trans-synaptic organizer, bridging presynaptic neurexins to postsynaptic delta-type glutamate receptors to maintain synapses and tune receptor signaling [#3, #6]. It forms homomeric and heteromeric complexes with other cerebellins (CBLN1, CBLN3, CBLN4), and heteromer formation modulates secretion and receptor affinity [#3, #5]. CBLN2 binds selectively to α- and β-neurexins carrying the splice site 4 insert [NRXs(S4+)] in a Ca2+-independent manner and simultaneously to postsynaptic GluD1/GluD2 (GluRδ1/δ2), assembling a tripartite neurexin–CBLN2–GluD complex; through this complex it induces presynaptic differentiation in cultured cerebellar, hippocampal, and cortical neurons, with a preference for inhibitory differentiation relative to neuroligin 1 [#0, #1, #2, #6]. In vivo, CBLN2 is required not for initial synaptogenesis but for long-term synapse maintenance and circuit-specific control of glutamate receptor responses: at CA1→subiculum and prefrontal synapses, Nrxn1SS4+–CBLN2 signaling enhances NMDA-receptor responses while Nrxn3SS4+–CBLN2 signaling suppresses AMPA-receptor responses, and Cbln1/2 loss reduces hippocampal excitatory synapse density in aging mice and produces salience-induced seizures [#7, #9]. It shows partial functional redundancy with CBLN1 in cerebellum yet non-redundant roles in other circuits [#4]. In the dorsal raphe, CBLN2 regulates serotonergic circuits, and its loss produces compulsive behaviors reversible by recombinant CBLN2 or serotonergic drugs [#8]. CBLN2 transcription is controlled by retinoic-acid signaling through a RARα-bound promoter and a Hominini-specific enhancer subject to SOX5 regulation that drives prefrontal dendritic spine formation [#10, #13]. Beyond the nervous system, CBLN2 acts in disease contexts: it is induced in sensory ganglia via SOX11-driven transcription and TET3-mediated promoter demethylation to drive neuropathic pain through NF-κB and ERK signaling [#14, #15], promotes pulmonary endothelial–mesenchymal transition via NF-κB/HIF-1α/Twist1 [#12], and suppresses oncogenic STAT3/PD-L1/β-catenin signaling in colorectal cancer [#17].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established CBLN2 as a gene distinct from CBLN1, defining the molecular identity that all subsequent functional work would build upon.\",\n      \"evidence\": \"Molecular cloning, sequence alignment, Southern blot, and genetic mapping in mouse\",\n      \"pmids\": [\"7877445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No functional role assigned at cloning\", \"Protein product and secretion not characterized\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed CBLN2 is a secreted glycoprotein capable of homo- and heteromeric assembly with other cerebellins, defining it as a secreted oligomeric signaling molecule rather than a cell-intrinsic factor.\",\n      \"evidence\": \"Heterologous cell transfection, Western blot, immunoprecipitation, and secretion assay\",\n      \"pmids\": [\"17331201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptors and synaptic targets not yet identified\", \"Stoichiometry of native complexes not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified the dual receptor system — presynaptic NRXs(S4+) and postsynaptic GluRδ1/δ2 — establishing CBLN2 as a bidirectional synaptic bridge that competes with neuroligin-mediated synaptogenesis.\",\n      \"evidence\": \"In vitro and co-culture synaptogenesis assays, pulldown binding, surface plasmon resonance, and Ca2+-sensitivity testing in cultured neurons\",\n      \"pmids\": [\"21410790\", \"22191730\", \"21356198\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of in vitro synaptogenesis unestablished\", \"Preference for inhibitory vs excitatory differentiation mechanism unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined CBLN2's place within the cerebellin family by demonstrating shared GluRδ2/neurexin binding and functional redundancy with CBLN1 in cerebellum but non-redundant roles elsewhere, and distinguished it from the DCC-binding CBLN4.\",\n      \"evidence\": \"Transgenic rescue of Cbln1-null Purkinje cells, Cbln2 knockout mice, receptor binding and displacement assays\",\n      \"pmids\": [\"22117778\", \"22220752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Circuit basis of non-redundant thalamic role not defined\", \"CBLN4-receptor finding is Medium-confidence single-lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Reframed CBLN2 from a synaptogenic factor to a maintenance factor by showing it assembles a tripartite NRX1β(S4+)–CBLN2–GluD1 complex required for long-term hippocampal synapse maintenance, not initial formation.\",\n      \"evidence\": \"Cbln2 single, double, and triple KO mice, electrophysiology, synapse density quantification, and seizure/behavioral phenotyping\",\n      \"pmids\": [\"29784783\", \"29691328\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism distinguishing maintenance from formation unresolved\", \"Why deficits manifest in aging not explained\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked CBLN2 to a behavioral circuit by showing it regulates dorsal raphe serotonergic function, with loss causing compulsive behavior reversible by recombinant protein and serotonergic drugs.\",\n      \"evidence\": \"Constitutive and conditional KO mice, behavioral assays, HPLC serotonin measurement, recombinant protein and pharmacological rescue\",\n      \"pmids\": [\"34158618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Synaptic substrate within raphe circuits not identified\", \"Connection between serotonin loss and synaptic role unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established RARα/retinoic-acid and a Hominini-specific SOX5-regulated enhancer as transcriptional drivers of CBLN2 controlling prefrontal expression and dendritic spine formation, providing an evolutionary and regulatory dimension.\",\n      \"evidence\": \"Comparative transcriptomics, enhancer/ChIP analysis, in situ genetic humanization of the mouse enhancer, dendritic spine quantification, and RA supplementation with RARα ChIP in a VPA autism model\",\n      \"pmids\": [\"34599306\", \"37247722\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct link from enhancer-driven expression to specific synaptic outputs incomplete\", \"VPA-model RARα axis is Medium-confidence single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Dissected circuit-specific receptor signaling, showing distinct neurexin splice isoforms route through CBLN2–GluD1 to oppositely modulate NMDA vs AMPA receptor responses without changing synapse number.\",\n      \"evidence\": \"Constitutive Cbln2 deletion, circuit-specific electrophysiology of AMPA/NMDA responses, spine/synapse density quantification across brain regions\",\n      \"pmids\": [\"36205393\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling from GluD1 to receptor modulation not defined\", \"How a single ligand produces opposite outputs is unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided a disease-relevant structural anchor by showing a GRID1/GluD1 amino-terminal variant disrupts GluD1–CBLN2 complex formation, implicating the interaction in synaptopathology.\",\n      \"evidence\": \"Site-directed mutagenesis and biochemical co-complex assay\",\n      \"pmids\": [\"37944084\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single biochemical assay without in vivo synaptic readout\", \"Disease causality not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended CBLN2 beyond synaptic maintenance into pathological signaling by showing transcriptional/epigenetic induction (SOX11, TET3 demethylation) drives neuropathic pain through NF-κB and ERK, and that CBLN2 acts in non-neural disease via NF-κB/HIF-1α/Twist1 in pulmonary endothelium and STAT3/PD-L1/β-catenin in colorectal cancer.\",\n      \"evidence\": \"ChIP, methylation assays, in vivo siRNA knockdown, exogenous protein and pathway inhibitors with behavioral, electrophysiological, and tumor readouts; plus overexpression/EndMT cell and animal models\",\n      \"pmids\": [\"41162740\", \"40665237\", \"37355224\", \"39577217\", \"29705514\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating pro-inflammatory/EndMT signaling not identified\", \"Relationship between synaptic NRX/GluD function and non-neural signaling unknown\", \"All single-lab findings\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CBLN2–GluD1 engagement transduces opposite, circuit-specific modulation of AMPA versus NMDA receptors and what receptor mediates its non-synaptic NF-κB/ERK/HIF-1α actions remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No downstream signaling mechanism from GluD1 defined\", \"No receptor identified for peripheral/disease signaling\", \"No structural model of the native tripartite complex\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 1, 6]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [6, 9]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [6, 9]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"complexes\": [\n      \"neurexin(S4+)–CBLN2–GluD1 tripartite trans-synaptic complex\"\n    ],\n    \"partners\": [\n      \"NRXN1\",\n      \"NRXN3\",\n      \"GRID1\",\n      \"GRID2\",\n      \"CBLN1\",\n      \"CBLN4\",\n      \"RARA\",\n      \"SOX5\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}